{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:45:40Z","timestamp":1776523540918,"version":"3.51.2"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10067-021-05700-z","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T06:02:31Z","timestamp":1616392951000},"page":"3533-3545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A practical approach for vaccinations including COVID-19 in autoimmune\/autoinflammatory rheumatic diseases: a non-systematic review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-7018","authenticated-orcid":false,"given":"Mehmet","family":"Soy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7289-1816","authenticated-orcid":false,"given":"G\u00f6khan","family":"Keser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-7461","authenticated-orcid":false,"given":"Pamir","family":"Atagunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0598-5737","authenticated-orcid":false,"given":"Melek Yal\u00e7in","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-844X","authenticated-orcid":false,"given":"Alper","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4730-2025","authenticated-orcid":false,"given":"Gizem","family":"Koyba\u015fi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-2991","authenticated-orcid":false,"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"1","key":"5700_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4102\/safp.v62i1.5123","volume":"62","author":"R Kaswa","year":"2020","unstructured":"Kaswa R, Govender I (2020) Novel coronavirus pandemic: a clinical overview. S Afr Fam Pract (2004) 62(1):e1\u2013e5. https:\/\/doi.org\/10.4102\/safp.v62i1.5123","journal-title":"S Afr Fam Pract (2004)"},{"issue":"8","key":"5700_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"},{"key":"5700_CR3","doi-asserted-by":"publisher","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, et al.(2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395(10224):565-574. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8.","DOI":"10.1016\/S0140-6736(20)30251-8"},{"issue":"2","key":"5700_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11684-020-0767-8","volume":"14","author":"M Zhou","year":"2020","unstructured":"Zhou M, Zhang X, Qu J (2020) Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 14(2):126\u2013135. https:\/\/doi.org\/10.1007\/s11684-020-0767-8","journal-title":"Front Med"},{"key":"5700_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","volume":"92","author":"Y Chen","year":"2020","unstructured":"Chen Y, Liu Q, Guo D (2020) Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92:418\u2013423. https:\/\/doi.org\/10.1002\/jmv.25681","journal-title":"J Med Virol"},{"issue":"10229","key":"5700_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054\u20131062. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"5700_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.4103\/ijmr.IJMR_957_20","volume":"151","author":"GM Varghese","year":"2020","unstructured":"Varghese GM, John R, Manesh A, Karthik R, Abraham OC (2020) Clinical management of COVID-19. Indian J Med Res 151:401\u2013410. https:\/\/doi.org\/10.4103\/ijmr.IJMR_957_20","journal-title":"Indian J Med Res"},{"key":"5700_CR8","unstructured":"World Health Organization. Draft landscape of COVID-19 candidate vaccines. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Last accessed 29.12.2020."},{"key":"5700_CR9","unstructured":"https:\/\/www.fda.gov\/media\/144412\/download. Last accessed 04.01.2021"},{"key":"5700_CR10","unstructured":"https:\/\/www.fda.gov\/media\/144636\/download. Last accessed 04.01.2021"},{"issue":"4","key":"5700_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3899\/jrheum.130667.","volume":"41","author":"L Broten","year":"2014","unstructured":"Broten L, Avi\u00f1a-Zubieta JA, Lacaille D, Joseph L, Hanly JG, Lix L, O'Donnell S, Barnabe C, Fortin PR, Hudson M, Jean S, Peschken C, Edworthy SM, Svenson L, Pineau CA, Clarke AE, Smith M, B\u00e9lisle P, Badley EM, Bergeron L, Bernatsky S (2014) Systemic autoimmune rheumatic disease prevalence in Canada: updated analyses across 7 provinces. J Rheumatol 41(4):673\u2013679. https:\/\/doi.org\/10.3899\/jrheum.130667.","journal-title":"J Rheumatol"},{"key":"5700_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/s2468-1253(20)30295-8.","volume":"5","author":"A Kumar","year":"2020","unstructured":"Kumar A, Quraishi MN, Segal JP, Raine T, Brookes MJ (2020) COVID-19 vaccinations in patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol 5:965\u2013966. https:\/\/doi.org\/10.1016\/s2468-1253(20)30295-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5700_CR13","doi-asserted-by":"publisher","unstructured":"Velikova T, Georgiev T (2021) SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-021-04792-9","DOI":"10.1007\/s00296-021-04792-9"},{"key":"5700_CR14","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.jaut.2020.102506.","volume":"114","author":"Y Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, Ram\u00edrez-Santana C, Costanzo A, Ridgway WM, Ansari AA, Gershwin ME, Selmi C, Anaya JM (2020) Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun 114:102506. https:\/\/doi.org\/10.1016\/j.jaut.2020.102506.","journal-title":"J Autoimmun"},{"key":"5700_CR15","unstructured":"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/underlying-conditions.html. Last accessed: 12 Jan 2021"},{"issue":"34","key":"5700_CR16","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1073\/pnas.1400472111","volume":"111","author":"S Plotkin","year":"2014","unstructured":"Plotkin S (2014) History of vaccination. Proc Natl Acad Sci U S A 111(34):12283\u201312287. https:\/\/doi.org\/10.1073\/pnas.1400472111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5700_CR17","unstructured":"Kelly DF, Rappuoli R (2005) Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Hot topics in infection and immunity in children II: Springer; p 217\u201323"},{"key":"5700_CR18","doi-asserted-by":"publisher","first-page":"C14","DOI":"10.1016\/j.vaccine.2010.07.020","volume":"28","author":"F Zepp","year":"2010","unstructured":"Zepp F (2010) Principles of vaccine design-lessons from nature. Vaccine (Basel) 28:C14\u2013C24","journal-title":"Vaccine (Basel)"},{"issue":"6","key":"5700_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-020-01744-7","volume":"21","author":"J Wang","year":"2020","unstructured":"Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. (2020) The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech 21(6):1\u201312","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"5700_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","volume":"28","author":"G Forni","year":"2021","unstructured":"Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome (2021) COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28(2):626\u2013639. https:\/\/doi.org\/10.1038\/s41418-020-00720-9","journal-title":"Cell Death Differ"},{"issue":"1","key":"5700_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/vaccines9010030","volume":"9","author":"BM Pr\u00fc\u03b2","year":"2021","unstructured":"Pr\u00fc\u03b2 BM (2021) Current state of the first COVID-19 vaccines. Vaccines (Basel) 9(1):30","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"5700_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243.","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines \u2014 a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"key":"5700_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/cmi.2017.151","volume":"15","author":"Y Segal","year":"2018","unstructured":"Segal Y, Shoenfeld Y (2018) Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 15:586\u2013594. https:\/\/doi.org\/10.1038\/cmi.2017.151","journal-title":"Cell Mol Immunol"},{"key":"5700_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","volume":"100","author":"LE uimar\u00e3es","year":"2015","unstructured":"uimar\u00e3es LE, Baker B, Perricone C, Shoenfeld Y (2015) Vaccines, adjuvants and autoimmunity. Pharmacol Res 100:190\u2013209. https:\/\/doi.org\/10.1016\/j.phrs.2015.08.003","journal-title":"Pharmacol Res"},{"issue":"2","key":"5700_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10067-017-3748-9.","volume":"37","author":"A Watad","year":"2018","unstructured":"Watad A, Quaresma M, Bragazzi NL, Cervera R, Tervaert JWC, Amital H, Shoenfeld Y (2018) The autoimmune\/inflammatory syndrome induced by adjuvants (ASIA)\/Shoenfeld\u2019s syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol 37(2):483\u2013493. https:\/\/doi.org\/10.1007\/s10067-017-3748-9.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"5700_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.autrev.2017.05.012.","volume":"16","author":"B Wang","year":"2017","unstructured":"Wang B, Shao X, Wang D, Xu D, Zhang JA (2017) Vaccinations and risk of systemic lupus erythematosus and rheumatoid arthritis: a systematic review and meta-analysis. Autoimmun Rev 16(7):756\u2013765. https:\/\/doi.org\/10.1016\/j.autrev.2017.05.012.","journal-title":"Autoimmun Rev"},{"key":"5700_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.12688\/f1000research.22600.2","volume":"9","author":"P Bellavite","year":"2020","unstructured":"Bellavite P (2020) Causality assessment of adverse events following immunization: the problem of multifactorial pathology. F1000Research 9:170. https:\/\/doi.org\/10.12688\/f1000research.22600.2","journal-title":"F1000Research"},{"key":"5700_CR28","unstructured":"https:\/\/vac-lshtm.shinyapps.io\/ncov_vaccine_landscape\/ last Accessed 21 January 2021."},{"issue":"9396","key":"5700_CR29","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","volume":"362","author":"DC Wraith","year":"2003","unstructured":"Wraith DC, Goldman M, Lambert PH (2003) Vaccination and autoimmune disease: what is the evidence? Lancet 362(9396):1659\u20131666. https:\/\/doi.org\/10.1016\/S0140-6736(03)14802-7","journal-title":"Lancet"},{"issue":"2","key":"5700_CR30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/0961203311429556","volume":"21","author":"HF Soldevilla","year":"2012","unstructured":"Soldevilla HF, Briones SF, Navarra SV (2012) Systemic lupus erythematosus following HPV immunization or infection? Lupus 21(2):158\u2013161. https:\/\/doi.org\/10.1177\/0961203311429556","journal-title":"Lupus"},{"issue":"9","key":"5700_CR31","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1517\/14740338.2015.1073710","volume":"14","author":"B Baker","year":"2015","unstructured":"Baker B, E\u00e7a Guimar\u00e3es L, Tomljenovic L, Agmon-Levin N, Shoenfeld Y (2015) The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf 14(9):1387\u20131394. https:\/\/doi.org\/10.1517\/14740338.2015.1073710","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"5700_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/BOR.0000000000000398.","volume":"29","author":"Y Segal","year":"2017","unstructured":"Segal Y, Calabr\u00f2 M, Kanduc D, Shoenfeld Y (2017) Human papilloma virus and lupus: the virus, the vaccine and the disease. Curr Opin Rheumatol 29(4):331\u2013342. https:\/\/doi.org\/10.1097\/BOR.0000000000000398.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"5700_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","volume":"72","author":"CC Mok","year":"2013","unstructured":"Mok CC, Ho LY, Fong LS, To CH (2013) Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 72(5):659\u2013664. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201393","journal-title":"Ann Rheum Dis"},{"key":"5700_CR34","doi-asserted-by":"publisher","unstructured":"Furer, V., Rondaan, C., Heijstek, M.W., Agmon-Levin, N., Van Assen, S., Bijl, M., Breedveld, F.C., etal. (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79, 39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882.","DOI":"10.1136\/annrheumdis-2019-215882"},{"issue":"RR-5","key":"5700_CR35","first-page":"1","volume":"57","author":"R Harpaz","year":"2008","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) (2008) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57(RR-5):1\u201330 quiz CE2-4","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"5700_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.crohns.2013.08.008","volume":"8","author":"Y Hagihara","year":"2014","unstructured":"Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, Kamata N, Sogawa M, Shiba M, Tanigawa T, Tominaga K, Watanabe T, Fujiwara Y, Hirota Y, Arakawa T (2014) Infliximab and\/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis 8(3):223\u2013233. https:\/\/doi.org\/10.1016\/j.crohns.2013.08.008","journal-title":"J Crohns Colitis"},{"issue":"1","key":"5700_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13075-015-0663-9","volume":"17","author":"L Fischer","year":"2015","unstructured":"Fischer L, Gerstel PF, Poncet A, Siegrist CA, Laffitte E, Gabay C, Seebach JD, Ribi C (2015) Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases\u2014a longitudinal study. Arthritis Res Ther 17(1):151. https:\/\/doi.org\/10.1186\/s13075-015-0663-9","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5700_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","volume":"43","author":"MA Friedman","year":"2017","unstructured":"Friedman MA, Winthrop KL (2017) Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist. Rheum Dis Clin N Am 43(1):1\u201313. https:\/\/doi.org\/10.1016\/j.rdc.2016.09.003","journal-title":"Rheum Dis Clin N Am"},{"key":"5700_CR39","doi-asserted-by":"publisher","unstructured":"Perry LM, Winthrop KL, Curtis JR (2014) Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep 16. https:\/\/doi.org\/10.1007\/s11926-014-0431-x","DOI":"10.1007\/s11926-014-0431-x"},{"issue":"8","key":"5700_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/RHU.0000000000000877.","volume":"25","author":"S Intongkam","year":"2019","unstructured":"Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S (2019) Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and\/or biologics therapy. J Clin Rheumatol 25(8):329\u2013334. https:\/\/doi.org\/10.1097\/RHU.0000000000000877.","journal-title":"J Clin Rheumatol"},{"key":"5700_CR41","doi-asserted-by":"publisher","unstructured":"Smolen, J.S., Landew\u00e9, R.B.M., Bijlsma, J.W.J., Burmester, G.R., Dougados, M., Kerschbaumer, A., et al., (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases 79(6):685-699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","DOI":"10.1136\/annrheumdis-2019-216655"},{"issue":"12","key":"5700_CR42","first-page":"2555","volume":"29","author":"M Abu-Shakra","year":"2002","unstructured":"Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D (2002) Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 29(12):2555\u20132557","journal-title":"J Rheumatol"},{"issue":"2","key":"5700_CR43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1136\/annrheumdis-2018-214025","volume":"78","author":"JK Park","year":"2019","unstructured":"Park JK, Lee YJ, Bitoun S, Winthrop KL, Choi Y, Lee EB, Mariette X (2019) Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 78(2):282\u2013284. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5700_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3899\/jrheum.170710","volume":"45","author":"S Subesinghe","year":"2018","unstructured":"Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB (2018) A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol 45(6):733\u2013744. https:\/\/doi.org\/10.3899\/jrheum.170710","journal-title":"J Rheumatol"},{"key":"5700_CR45","doi-asserted-by":"publisher","first-page":"R2","DOI":"10.1186\/ar4427","volume":"16","author":"MC Kapetanovic","year":"2014","unstructured":"Kapetanovic MC, Kristensen L-E, Saxne T, Aktas T, M\u00f6rner A, Geborek P (2014) Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 16:R2. https:\/\/doi.org\/10.1186\/ar4427","journal-title":"Arthritis Res Ther"},{"key":"5700_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/ard.2005.036434","volume":"65","author":"I Fomin","year":"2006","unstructured":"Fomin I (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF blockers. Ann Rheum Dis 65:191\u2013194. https:\/\/doi.org\/10.1136\/ard.2005.036434","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5700_CR47","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1136\/annrheumdis-2019-215187","volume":"78","author":"JK Park","year":"2019","unstructured":"Park JK, Choi Y, Winthrop KL, Song YW, Lee EB (2019) Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial. Ann Rheum Dis 78(9):1283\u20131284. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215187","journal-title":"Ann Rheum Dis"},{"key":"5700_CR48","doi-asserted-by":"publisher","unstructured":"Mehta P, Sanchez E, Moraitis E, Longley N, Lendrem DW, Giles IP, Chambers RC, Ciurtin C, Isaacs JD (2020) Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/s2665-9913(20)30392-1","DOI":"10.1016\/s2665-9913(20)30392-1"},{"issue":"12","key":"5700_CR49","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/art.30580","volume":"63","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic MC, Roseman C, J\u00f6nsson G, Truedsson L, Saxne T, Geborek P (2011) Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 63(12):3723\u20133732. https:\/\/doi.org\/10.1002\/art.30580","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5700_CR50","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1186\/ar3542","volume":"13","author":"JJ Kobie","year":"2011","unstructured":"Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I (2011) Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 13(6):R209. https:\/\/doi.org\/10.1186\/ar3542","journal-title":"Arthritis Res Ther"},{"key":"5700_CR51","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1007\/s00296-011-2118-1","volume":"32","author":"M Iwamoto","year":"2012","unstructured":"Iwamoto M, Homma S, Onishi S, Kamata Y, Nagatani K, Yamagata Z, Minota S (2012) Low level of seroconversion after a novel influenza A\/H1N1\/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 32:3691\u20133694. https:\/\/doi.org\/10.1007\/s00296-011-2118-1","journal-title":"Rheumatol Int"},{"issue":"11","key":"5700_CR52","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","volume":"51","author":"IL Franca","year":"2012","unstructured":"Franca IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E (2012) TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 51(11):2091\u20132098. https:\/\/doi.org\/10.1093\/rheumatology\/kes202","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5700_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jbspin.2015.02.016.","volume":"83","author":"M Michel","year":"2016","unstructured":"Michel M, Vincent FB, Rio S, Leon N, Marcelli C (2016) Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs. Joint Bone Spine 83(2):237\u2013238. https:\/\/doi.org\/10.1016\/j.jbspin.2015.02.016.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"5700_CR54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","volume":"45","author":"MC Kapetanovic","year":"2006","unstructured":"Kapetanovic MC, Saxne T, Sj\u00f6holm A, Truedsson L, J\u00f6nsson G, Geborek P (2006) Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45(1):106\u2013111. https:\/\/doi.org\/10.1093\/rheumatology\/kei193","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5700_CR55","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1136\/annrheumdis-2013-203389","volume":"72","author":"MK Nisar","year":"2013","unstructured":"Nisar MK, Ostor AJ (2013) TNF antagonists and shingles: is vaccination advisable? Ann Rheum Dis 72(5):e1. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203389","journal-title":"Ann Rheum Dis"},{"key":"5700_CR56","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1128\/cvi.00386-12","volume":"19","author":"A Chioato","year":"2012","unstructured":"Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H (2012) Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, Randomized Single-Center Study. Clin Vaccine Immunol 19:1597\u20131602. https:\/\/doi.org\/10.1128\/cvi.00386-12","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"5700_CR57","doi-asserted-by":"publisher","first-page":"e001018","DOI":"10.1136\/rmdopen-2019-001018.","volume":"5","author":"P Richi","year":"2019","unstructured":"Richi P, Mart\u00edn MD, de Ory F, Guti\u00e9rrez-Larraya R, Casas I, Jim\u00e9nez-D\u00edaz AM, Cava F, Mu\u00f1oz-Fernandez S (2019) Secukinumab does not impair the immunogenic response to the influenza vaccine in patients. RMD Open 5(2):e001018. https:\/\/doi.org\/10.1136\/rmdopen-2019-001018.","journal-title":"RMD Open"},{"issue":"4","key":"5700_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.vaccine.2019.10.081","volume":"38","author":"V Furer","year":"2020","unstructured":"Furer V, Zisman D, Kaufman I, Arad U, Berman M, Sarbagil-Maman H, Elias M, Hadad A, Paran D, Drori Y, Friedman N, Mandelboim M, Elkayam O (2020) Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab. Vaccine 38(4):847\u2013851. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.081","journal-title":"Vaccine"},{"issue":"6","key":"5700_CR59","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40259-017-0249-y.","volume":"31","author":"EV Gomez","year":"2017","unstructured":"Gomez EV, Bishop JL, Jackson K, Muram TM, Phillips D (2017) Response to tetanus and pneumococcal vaccination following administration of ixekizumab in healthy participants. BioDrugs. 31(6):545\u2013554. https:\/\/doi.org\/10.1007\/s40259-017-0249-y.","journal-title":"BioDrugs."},{"key":"5700_CR60","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","volume":"39","author":"M Soy","year":"2020","unstructured":"Soy M, Keser G, Atag\u00fcnd\u00fcz P, Tabak F, Atag\u00fcnd\u00fcz I, Kayhan S (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39:2085\u20132094. https:\/\/doi.org\/10.1007\/s10067-020-05190-5","journal-title":"Clin Rheumatol"},{"issue":"12","key":"5700_CR61","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","volume":"71","author":"S Mori","year":"2012","unstructured":"Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K (2012) Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 71(12):2006\u20132010. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201950","journal-title":"Ann Rheum Dis"},{"key":"5700_CR62","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","volume":"74","author":"CO Bingham","year":"2015","unstructured":"Bingham CO, Rizzo W, Kivitz A, Hassanal A, Upmanyu R, Klearman M (2015) Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 74:818\u2013822. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204427","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5700_CR63","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/14397595.2013.843743","volume":"24","author":"T Tsuru","year":"2014","unstructured":"Tsuru T, Terao K, Murakami M, Matsutani T, Suzaki M, Amamoto T, Nakashima H, Akiyama A, Nishimoto N (2014) Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 24(3):511\u2013516. https:\/\/doi.org\/10.3109\/14397595.2013.843743","journal-title":"Mod Rheumatol"},{"issue":"17","key":"5700_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12891-016-1082-z.","volume":"26","author":"R Alten","year":"2016","unstructured":"Alten R, Bingham CO 3rd, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC (2016) Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord 26(17):231. https:\/\/doi.org\/10.1186\/s12891-016-1082-z.","journal-title":"BMC Musculoskelet Disord"},{"key":"5700_CR65","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","volume":"72","author":"N Ter Haar","year":"2013","unstructured":"Ter Haar N, Lachmann H, \u00d6zen S, Woo P, Uziel Y, Modesto C, Kon\u00e9-Paut I, Cantarini L, Insalaco A, Neven B, Hofer M, Rigante D, Al-Mayouf S, Touitou I, Gallizzi R, Papadopoulou-Alataki E, Martino S, Kuemmerle-Deschner J, Obici L, Iagaru N, Simon A, Nielsen S, Martini A, Ruperto N, Gattorno M, Frenkel J (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678\u2013685. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201268","journal-title":"Ann Rheum Dis"},{"key":"5700_CR66","doi-asserted-by":"publisher","unstructured":"Furer V, Rondaan C, Heijstek M, Van Assen S, Bijl M, Agmon-Levin N, Breedveld FC, et al. (2019). Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients wit. RMD Open 5, e001041. https:\/\/doi.org\/10.1136\/rmdopen-2019-001041","DOI":"10.1136\/rmdopen-2019-001041"},{"key":"5700_CR67","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2010.137216","volume":"70","author":"S Van Assen","year":"2011","unstructured":"Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JPA, Jayne DRW, Kallenberg CGM, M\u00fcller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414\u2013422. https:\/\/doi.org\/10.1136\/ard.2010.137216","journal-title":"Ann Rheum Dis"},{"key":"5700_CR68","doi-asserted-by":"publisher","unstructured":"Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Kon\u00e9-Paut I, Fasth A, Minden K, Ravelli A, Abinun M, Pileggi GS, Borte M, Wulffraat NM; EULAR (2011). EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70(10):1704-1712. https:\/\/doi.org\/10.1136\/ard.2011.150193","DOI":"10.1136\/ard.2011.150193"},{"issue":"9","key":"5700_CR69","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","volume":"74","author":"NM Ter Haar","year":"2015","unstructured":"Ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, Cantarini L, Galeotti C, Grateau G, Hentgen V, Hofer M, Kallinich T, Kone-Paut I, Lachmann HJ, Ozdogan H, Ozen S, Russo R, Simon A, Uziel Y, Wouters C, Feldman BM, Vastert SJ, Wulffraat NM, Benseler SM, Frenkel J, Gattorno M, Kuemmerle-Deschner JB (2015) Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 74(9):1636\u20131644. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207546","journal-title":"Ann Rheum Dis"},{"key":"5700_CR70","doi-asserted-by":"publisher","unstructured":"Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, Dedeoglu F, Baris EH, Vastert SJ, Wulffraat NM, Frenkel J (2018) The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatr Rheumatol 16. https:\/\/doi.org\/10.1186\/s12969-018-0235-z","DOI":"10.1186\/s12969-018-0235-z"},{"key":"5700_CR71","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1128\/cvi.00175-10","volume":"17","author":"A Chioato","year":"2010","unstructured":"Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, Kleinschmidt A (2010) Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1\u03b2-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin Vaccine Immunol 17:1952\u20131957. https:\/\/doi.org\/10.1128\/cvi.00175-10","journal-title":"Clin Vaccine Immunol"},{"key":"5700_CR72","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1186\/1546-0096-13-s1-p1","volume":"13","author":"P Brogan","year":"2015","unstructured":"Brogan P, Hofer M, Kuemmerle-Deschner J, Lauwerys B, Speziale A, Abrams K, Leon K, Wei X, Laxer R (2015) Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with canakinumab. Pediatr Rheumatol 13:P1. https:\/\/doi.org\/10.1186\/1546-0096-13-s1-p1","journal-title":"Pediatr Rheumatol"},{"key":"5700_CR73","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer J-M, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70:747\u2013754. https:\/\/doi.org\/10.1136\/ard.2010.134254","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"5700_CR74","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1001\/jama.2013.6768","volume":"309","author":"MW Heijstek","year":"2013","unstructured":"Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, Smits GP, van Gageldonk PG, Berbers GA, Wulffraat NM (2013) Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA 309(23):2449\u20132456. https:\/\/doi.org\/10.1001\/jama.2013.6768","journal-title":"JAMA"},{"issue":"12","key":"5700_CR75","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2011.152728.","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, Leslie KS, Jim\u00e9nez S, Morell-Dubois S, Davis N, Patel N, Widmer A, Preiss R, Lachmann HJ (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70(12):2095\u20132102. https:\/\/doi.org\/10.1136\/ard.2011.152728.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5700_CR76","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/rheumatology\/kex185.","volume":"56","author":"VK Jaeger","year":"2017","unstructured":"Jaeger VK, Hoffman HM, van der Poll T, Tilson H, Seibert J, Speziale A, Junge G, Franke K, Vritzali E, Hawkins PN, Kuemmerle-Deschner J, Walker UA (2017) Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology (Oxford) 56(9):1484\u20131491. https:\/\/doi.org\/10.1093\/rheumatology\/kex185.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5700_CR77","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s10067-020-05042-2","volume":"39","author":"P Richi","year":"2020","unstructured":"Richi P, Alonso O, Mart\u00edn MD, Gonz\u00e1lez-Hombrado L, Nav\u00edo T, Salido M, Llorente J, Andreu-V\u00e1zquez C, Garc\u00eda-Fern\u00e1ndez C, Jim\u00e9nez-Diaz A, Lojo L, Cebri\u00e1n L, Thuissard-Vasallo I, Mart\u00ednez de Aramayona MJ, Cobo T, Garc\u00eda-Castro M, Castro P, Fern\u00e1ndez-Castro M, Illera \u00d3, Steiner M, Mu\u00f1oz-Fern\u00e1ndez S (2020) Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study. Clin Rheumatol 39(9):2751\u20132756. https:\/\/doi.org\/10.1007\/s10067-020-05042-2","journal-title":"Clin Rheumatol"},{"key":"5700_CR78","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S Van Assen","year":"2010","unstructured":"Van Assen S, Holvast A, Benne CA, Posthumus MD, Van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, De Haan A, Westra J, Kallenberg CGM, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62:75\u201381. https:\/\/doi.org\/10.1002\/art.25033","journal-title":"Arthritis Rheum"},{"key":"5700_CR79","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2013","unstructured":"Hua C, Barnetche T, Combe B, Morel J (2013) Effect of methotrexate, antitumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis:a systematic review and meta-analysis. Arthritis Care Res 66:1016\u20131026","journal-title":"Arthritis Care Res"},{"key":"5700_CR80","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.13495","volume":"202","author":"D Baker","year":"2020","unstructured":"Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202:149\u2013161. https:\/\/doi.org\/10.1111\/cei.13495","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"5700_CR81","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1186\/ar4358","volume":"15","author":"M Crnkic Kapetanovic","year":"2013","unstructured":"Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P (2013) Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 15(5):R171","journal-title":"Arthritis Res Ther"},{"key":"5700_CR82","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard.2007.077461","volume":"67","author":"S Oren","year":"2008","unstructured":"Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 67:937\u2013941. https:\/\/doi.org\/10.1136\/ard.2007.077461","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5700_CR83","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","volume":"29","author":"U Arad","year":"2011","unstructured":"Arad U, Tzadok S, Amir S et al (2011) The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 29(8):1643\u20131648","journal-title":"Vaccine."},{"key":"5700_CR84","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/ar3047","volume":"12","author":"M Rehnberg","year":"2010","unstructured":"Rehnberg M, Brisslert M, Amu S, Zendjanchi K, H\u00e5wi G, Bokarewa MI (2010) Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 12:R111. https:\/\/doi.org\/10.1186\/ar3047","journal-title":"Arthritis Res Ther"},{"key":"5700_CR85","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/cei.12390","volume":"178","author":"J Westra","year":"2014","unstructured":"Westra J, Van Assen S, Wilting KR, Land J, Horst G, De Haan A, Bijl M (2014) Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol 178:40\u201347. https:\/\/doi.org\/10.1111\/cei.12390","journal-title":"Clin Exp Immunol"},{"key":"5700_CR86","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","volume":"33","author":"RA Eisenberg","year":"2013","unstructured":"Eisenberg RA, Jawad AF, Boyer J, Maurer K, Mcdonald K, Prak ETL, Sullivan KE (2013) Rituximab-treated patients have a poor response to \u0131nfluenza vaccination. J Clin Immunol 33:388\u2013396. https:\/\/doi.org\/10.1007\/s10875-012-9813-x","journal-title":"J Clin Immunol"},{"issue":"5","key":"5700_CR87","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/ard.2007.077552.","volume":"67","author":"LB Gelinck","year":"2008","unstructured":"Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA et al (2008) The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67(5):713\u2013716. https:\/\/doi.org\/10.1136\/ard.2007.077552.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5700_CR88","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/art.30325","volume":"63","author":"C Gabay","year":"2011","unstructured":"Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA, H1N1 Study Group (2011) Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 63(6):1486\u20131496. https:\/\/doi.org\/10.1002\/art.30325","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5700_CR89","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034.XXX","volume":"62","author":"CO Bingham 3rd","year":"2010","unstructured":"Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62(1):64\u201374. https:\/\/doi.org\/10.1002\/art.25034.XXX","journal-title":"Arthritis Rheum"},{"key":"5700_CR90","doi-asserted-by":"publisher","unstructured":"B\u00fchler S, Eperon G, Ribi C, Kyburz D, Van G, Visser L, Siegrist C, Hat C (2015) Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. https:\/\/doi.org\/10.4414\/smw.2015.14159","DOI":"10.4414\/smw.2015.14159"},{"issue":"8","key":"5700_CR91","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.autrev.2011.10.015.","volume":"11","author":"M Bijl","year":"2012","unstructured":"Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y (2012) Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 11(8):572\u2013576. https:\/\/doi.org\/10.1016\/j.autrev.2011.10.015.","journal-title":"Autoimmun Rev"},{"key":"5700_CR92","doi-asserted-by":"publisher","unstructured":"Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM. (2007) Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66(10):1402-1403. https:\/\/doi.org\/10.1136\/ard.2007.071878.","DOI":"10.1136\/ard.2007.071878"},{"issue":"5","key":"5700_CR93","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1186\/ar4358","volume":"15","author":"M Crnkic Kapetanovic","year":"2013","unstructured":"Crnkic Kapetanovic M, Saxne T, J\u00f6nsson G, Truedsson L, Geborek P (2013) Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 15(5):R171. https:\/\/doi.org\/10.1186\/ar4358","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"5700_CR94","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/ar3047","volume":"12","author":"M Rehnberg","year":"2010","unstructured":"Rehnberg M, Brisslert M, Amu S, Zendjanchi K, H\u00e5wi G, Bokarewa MI (2010) Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 12(3):R111. https:\/\/doi.org\/10.1186\/ar3047","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5700_CR95","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. (2016) The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 75(4):687\u2013695. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207191","journal-title":"Ann Rheum Dis"},{"key":"5700_CR96","doi-asserted-by":"publisher","unstructured":"Shimabukuro T, Nair N (2021) Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. https:\/\/doi.org\/10.1001\/jama.2021.0600","DOI":"10.1001\/jama.2021.0600"},{"key":"5700_CR97","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99\u2013111. https:\/\/doi.org\/10.1016\/s0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"5700_CR98","unstructured":"https:\/\/www.rheumatology.org.uk\/practice-quality\/covid-19-guidance; last accessed 12.01.2021."},{"key":"5700_CR99","unstructured":"https:\/\/dgrh.de\/Start\/Wissenschaft\/Forschung\/COVID-19\/Impfung-gegen-SARS-CoV2.html) last accessed 12.01.2021."},{"key":"5700_CR100","unstructured":"https:\/\/www.rheumatology.org\/About-Us\/Newsroom\/Press-Releases\/ID\/1138"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05700-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05700-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T09:13:39Z","timestamp":1628673219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05700-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5700"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05700-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Since it is a review article, we have no ethical approval, and we declared that all procedures performed in the present study were in accordance with the ethical standards of the institutional and\/ or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All of the authors accepted the last version of the article and signed the author\u2019s disclosure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All of the authors accepted the last version of the article for publication and signed the author\u2019s disclosure.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"No code or software.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}